Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
05 sept. 2023 07h59 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...